VANGUARD PORTFOLIO MANAGEMENT LLC
Position in FDMT — 4D Molecular Therapeutics, Inc.
CIK 2100121
MALVERN, PA
Position in FDMT
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$5,174,767
New position
Shares Held
555,829
first reported quarter
Ownership
0.803%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Biotechnology
Healthcare · as of Mar 31, 2026VANGUARD PORTFOLIO MANAGEMENT LLC holds $390,107,992 across 6 Biotechnology names. FDMT ranks #3 (1.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PTGX |
Protagonist Therapeutics, Inc
|
3,481,211 | $366,919,639 | |
| 2 | ELVN |
Enliven Therapeutics, Inc.
|
330,964 | $12,973,788 | |
| 3 | FDMT |
4D Molecular Therapeutics, Inc.
This page
|
555,829 | $5,174,767 | |
| 4 | SLDB |
Solid Biosciences Inc.
|
338,630 | $2,438,136 | |
| 5 | ABSI |
Absci Corp
|
801,063 | $2,403,189 | |
| 6 | BDTX |
Black Diamond Therapeutics, Inc.
|
93,180 | $198,473 |
All Filings in FDMT
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $5,174,767 | 555,829 | Shares | Defined | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||